

# Gayatri Amirthalingam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8175878/publications.pdf>

Version: 2024-02-01

46  
papers

7,643  
citations

293460

24  
h-index

242451

47  
g-index

62  
all docs

62  
docs citations

62  
times ranked

11394  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e25803.	1.2	1
2	Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. <i>Journal of Infection</i> , 2022, 84, 675-683.	1.7	87
3	Extended interval BNT162b2 vaccination enhances peak antibody generation. <i>Npj Vaccines</i> , 2022, 7, 14.	2.9	101
4	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2022, 386, 340-350.	13.9	501
5	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. <i>New England Journal of Medicine</i> , 2022, 386, 1532-1546.	13.9	1,709
6	Long-Term Health-Related Quality of Life in Non-Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal Analysis and Cross-Sectional Comparison With Controls. <i>Clinical Infectious Diseases</i> , 2022, 75, e962-e973.	2.9	32
7	Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network. <i>Journal of Infection</i> , 2022, 84, 814-824.	1.7	8
8	Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e24341.	1.2	22
9	Rapid community point-of-care testing for COVID-19 (RAPTOR-C19): protocol for a platform diagnostic study. <i>Diagnostic and Prognostic Research</i> , 2021, 5, 4.	0.8	7
10	Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	34
11	Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. <i>Nature Immunology</i> , 2021, 22, 620-626.	7.0	320
12	The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system. <i>Eurosurveillance</i> , 2021, 26, .	3.9	10
13	Adverse events of interest following influenza vaccination, a comparison of cell culture-based with egg-based alternatives: English sentinel network annual report paper 2019/20. <i>Lancet Regional Health - Europe</i> , The, 2021, 2, 100029.	3.0	7
14	Obstetric and perinatal health outcomes after pertussis vaccination during pregnancy in Ontario, Canada: a retrospective cohort study. <i>CMAJ Open</i> , 2021, 9, E349-E349.	1.1	9
15	Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. <i>Journal of Infection</i> , 2021, 82, 162-169.	1.7	61
16	Social determinants of pertussis and influenza vaccine uptake in pregnancy: a national cohort study in England using electronic health records. <i>BMJ Open</i> , 2021, 11, e046545.	0.8	11
17	Seroprevalence of SARS-CoV-2 among Blood Donors and Changes after Introduction of Public Health and Social Measures, London, UK. <i>Emerging Infectious Diseases</i> , 2021, 27, 1795-1801.	2.0	18
18	Retrospective cohort study investigating extent of pertussis transmission during a boarding school outbreak, England, December 2017 to June 2018. <i>Eurosurveillance</i> , 2021, 26, .	3.9	4

#	ARTICLE	IF	CITATIONS
19	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. <i>New England Journal of Medicine</i> , 2021, 385, 585-594.	13.9	2,411
20	mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant. <i>ELife</i> , 2021, 10, .	2.8	28
21	Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5â€“6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. <i>The Lancet Healthy Longevity</i> , 2021, 2, e554-e560.	2.0	34
22	JMM Profile: Bordetella pertussis and whooping cough (pertussis): still a significant cause of infant morbidity and mortality, but vaccine-preventable. <i>Journal of Medical Microbiology</i> , 2021, 70, .	0.7	4
23	Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. <i>Nature Communications</i> , 2021, 12, 7217.	5.8	80
24	Delivering prenatal pertussis vaccine through maternity services in England: What is the impact on vaccine coverage?. <i>Vaccine</i> , 2020, 38, 5332-5336.	1.7	7
25	Impact of the herpes zoster vaccination programme on hospitalised and general practice consulted herpes zoster in the 5 years after its introduction in England: a population-based study. <i>BMJ Open</i> , 2020, 10, e037458.	0.8	8
26	Excess mortality in the first COVID pandemic peak: cross-sectional analyses of the impact of age, sex, ethnicity, household size, and long-term conditions in people of known SARS-CoV-2 status in England. <i>British Journal of General Practice</i> , 2020, 70, e890-e898.	0.7	51
27	Disparities in the excess risk of mortality in the first wave of COVID-19: Cross sectional study of the English sentinel network. <i>Journal of Infection</i> , 2020, 81, 785-792.	1.7	36
28	Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis. <i>BMJ Open</i> , 2020, 10, e034886.	0.8	14
29	Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1034-1042.	4.6	493
30	Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e18606.	1.2	66
31	The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e19773.	1.2	44
32	The Use of Quasi-experimental Designs for Vaccine Evaluation. <i>Clinical Infectious Diseases</i> , 2019, 68, 1769-1776.	2.9	20
33	Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. <i>Lancet Public Health</i> , The, 2018, 3, e82-e90.	4.7	57
34	Effectiveness of herpes zoster vaccination in an older United Kingdom population. <i>Vaccine</i> , 2018, 36, 2371-2377.	1.7	39
35	Vaccination in pregnancy: Attitudes of nurses, midwives and health visitors in England. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 179-188.	1.4	50
36	Hospitalisation of preterm infants with pertussis in the context of a maternal vaccination programme in England. <i>Archives of Disease in Childhood</i> , 2018, 103, 224-229.	1.0	22

#	ARTICLE	IF	CITATIONS
37	Review of vaccination in pregnancy to prevent pertussis in early infancy. <i>Journal of Medical Microbiology</i> , 2018, 67, 1426-1456.	0.7	80
38	RCGP Research and Surveillance Centre Annual Report 2014â€“2015: disparities in presentations to primary care. <i>British Journal of General Practice</i> , 2017, 67, e29-e40.	0.7	33
39	Sociodemographic predictors of variation in coverage of the national shingles vaccination programme in England, 2014/15. <i>Vaccine</i> , 2017, 35, 2372-2378.	1.7	21
40	Survey of Household Contacts of Infants With Laboratory-confirmed Pertussis Infection During a National Pertussis Outbreak in England and Wales. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 140-145.	1.1	21
41	Sustained Effectiveness of the Maternal Pertussis Immunization Program in England 3 Years Following Introduction. <i>Clinical Infectious Diseases</i> , 2016, 63, S236-S243.	2.9	223
42	Should the UK introduce a universal childhood varicella vaccination programme?. <i>Archives of Disease in Childhood</i> , 2016, 101, 2-3.	1.0	8
43	Oral Fluid Testing for Pertussis, England and Wales, June 2007â€“August 2009. <i>Emerging Infectious Diseases</i> , 2014, 20, 968-975.	2.0	22
44	Effectiveness of maternal pertussis vaccination in England: an observational study. <i>Lancet</i> , The, 2014, 384, 1521-1528.	6.3	593
45	Strategies to control pertussis in infants. <i>Archives of Disease in Childhood</i> , 2013, 98, 552-555.	1.0	71
46	Accelerating Control of Pertussis in England and Wales. <i>Emerging Infectious Diseases</i> , 2012, 18, 38-47.	2.0	74